Back
Science

Research Suggests GLP-1 Drugs May Be Linked to Increased Risk of Osteoporosis and Gout

Generated on: Last updated: 1 sources
View source

GLP-1 Drugs Linked to Slightly Elevated Risk of Osteoporosis and Gout, Study Suggests

Research presented at the American Academy of Orthopaedic Surgeons' annual meeting indicates that GLP-1 drugs, including semaglutide (Ozempic, Wegovy) and liraglutide (Victoza, Saxenda), may be associated with a slightly elevated risk of osteoporosis and gout. This finding emerged after observations of severe tendon tears in some patients following minor injuries, prompting Dr. John Horneff, lead author and associate professor of orthopedic surgery at the University of Pennsylvania, to initiate the study.

Dr. John Horneff initiated the study following observations of severe tendon tears in some patients after minor injuries.

Understanding the Conditions

Osteoporosis is characterized by weakened bones that are prone to fractures, a significant concern for older adults and individuals experiencing rapid weight loss.

Gout is a painful form of arthritis resulting from excess uric acid, a condition that can also be influenced by rapid weight loss.

The Study's Insights

The study analyzed five years of medical records from over 146,000 adults diagnosed with both obesity and Type 2 diabetes. The research compared patients actively using GLP-1 drugs with those not using them.

Key findings included:

  • Approximately 4% of GLP-1 users developed osteoporosis, compared to just over 3% of nonusers, representing an approximate 30% increased risk.
  • Osteomalacia, a condition involving bone softening, occurred about twice as often in GLP-1 users, though it was rare overall.
  • Rates of gout were 7.4% for GLP-1 users versus 6.6% for nonusers, an approximate 12% increased risk.

Dr. Horneff noted a nearly doubling of the risk for bone mineral density issues over a five-year period within the data.

Expert Perspectives and Caveats

Dr. Clifford Rosen, a professor of medicine at Tufts University not involved in the study, affirmed that weight loss can lead to bone loss. However, the observational nature of the research means it cannot definitively prove that the medications caused these conditions. The study also lacked detailed information on patients' diets, exercise habits, or supplement use, which are crucial factors.

These results align with other research, including a study published in February in the Journal of Clinical Endocrinology & Metabolism that linked GLP-1 drugs to an increased risk of osteoporosis-related fractures in older adults with Type 2 diabetes. The FDA label for semaglutide also mentions a potential increase in bone fracture risk in older adults and women.

Dr. Susan Spratt, an endocrinologist at Duke Health, questioned whether the increased risk is due to the rapid weight loss itself or another mechanism of the drug. She also noted that some studies suggest musculoskeletal benefits with GLP-1 drugs and improvements in joint pain among patients who lose weight.

Potential Mechanisms and Mitigation

Potential mechanisms for the observed link include reduced intake of essential nutrients like vitamin D and calcium due to appetite suppression, or changes in bone remodeling due to rapid weight loss. For gout, rapid weight loss can temporarily elevate uric acid levels, contributing to the condition.

Dr. Christopher McGowan, a gastroenterologist, suggested that combining GLP-1s with structured exercise could largely mitigate bone density loss.

Dr. McGowan emphasized that these findings should not alter prescribing practices but reinforce the need for comprehensive obesity treatment that includes guidance on protein intake, exercise, and bone health monitoring.